Shots:
- Ipsen has entered into an exclusive licensing agreement with Simcere Zaiming for SIM0613 to treat solid tumors with the highest unmet needs
- Ipsen will secure global rights to SIM0613 outside Greater China, gain manufacturing rights after technology transfer, & assume responsibility for all development activities beyond Greater China, incl. P-I preparation & IND/CTA submissions
- As per the terms, Simcere Zaiming will receive ~$1.06B in upfront, development, regulatory & commercial milestones, along with tiered sales royalties contingent upon successful development & regulatory approvals
Ref: Ipsen | Image: Ipsen & Simcere Zaiming | Press Release
Related News: Ipsen Acquires ImCheck Therapeutics, Enhancing its Oncology Leadership and Strengthening its Pipeline
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
